FDA approves PharmaMar’s Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
harmaMar (MSE:PHM) has announced that the U.S Food and Drug Administration (FDA) has granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with…
A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a…
AI finds undiagnosed liver disease in early stages #TLM2024 #AASLD24
Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed that an algorithm fueled by artificial intelligence can accurately detect early-stage…